E. Salah

2.9k total citations
47 papers, 1.4k citations indexed

About

E. Salah is a scholar working on Molecular Biology, Cancer Research and Organic Chemistry. According to data from OpenAlex, E. Salah has authored 47 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 10 papers in Cancer Research and 8 papers in Organic Chemistry. Recurrent topics in E. Salah's work include Epigenetics and DNA Methylation (13 papers), Cancer, Hypoxia, and Metabolism (10 papers) and Cancer-related gene regulation (8 papers). E. Salah is often cited by papers focused on Epigenetics and DNA Methylation (13 papers), Cancer, Hypoxia, and Metabolism (10 papers) and Cancer-related gene regulation (8 papers). E. Salah collaborates with scholars based in United Kingdom, United States and Japan. E. Salah's co-authors include Stefan Knapp, Christopher J. Schofield, F. von Delft, Anthony Tumber, Giulio Superti‐Furga, P. Rellos, Wen‐Hwa Lee, F. Niesen, Lennart Brewitz and A.C.W. Pike and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

E. Salah

44 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Salah United Kingdom 19 1.0k 239 172 153 149 47 1.4k
Richard A. Norman United Kingdom 18 1.0k 1.0× 269 1.1× 325 1.9× 165 1.1× 145 1.0× 26 1.5k
Tong Ying Shun United States 21 686 0.7× 223 0.9× 99 0.6× 139 0.9× 106 0.7× 35 1.4k
Jeffrey Tom United States 16 1.3k 1.2× 284 1.2× 218 1.3× 75 0.5× 102 0.7× 21 1.8k
Maria Fälth Savitski Germany 8 1.2k 1.2× 130 0.5× 134 0.8× 178 1.2× 60 0.4× 10 1.5k
Bainan Wu United States 22 880 0.9× 244 1.0× 150 0.9× 118 0.8× 63 0.4× 28 1.2k
Guixian Jin United States 15 714 0.7× 264 1.1× 108 0.6× 90 0.6× 174 1.2× 21 1.1k
Klaus Godl Germany 20 1.0k 1.0× 281 1.2× 165 1.0× 84 0.5× 84 0.6× 23 1.5k
Zoltán Greff Hungary 13 1.0k 1.0× 312 1.3× 225 1.3× 73 0.5× 69 0.5× 21 1.5k
Chunli Yan United States 22 1.3k 1.2× 130 0.5× 109 0.6× 121 0.8× 80 0.5× 46 1.5k
Dominico Vigil United States 19 1.7k 1.6× 396 1.7× 137 0.8× 144 0.9× 177 1.2× 26 2.0k

Countries citing papers authored by E. Salah

Since Specialization
Citations

This map shows the geographic impact of E. Salah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Salah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Salah more than expected).

Fields of papers citing papers by E. Salah

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Salah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Salah. The network helps show where E. Salah may publish in the future.

Co-authorship network of co-authors of E. Salah

This figure shows the co-authorship network connecting the top 25 collaborators of E. Salah. A scholar is included among the top collaborators of E. Salah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Salah. E. Salah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Laidlaw, Stephen M., E. Salah, Petra Lukacik, et al.. (2025). Silaproline-bearing nirmatrelvir derivatives are potent inhibitors of the SARS-CoV-2 main protease highlighting the value of silicon-derivatives in structure-activity-relationship studies. European Journal of Medicinal Chemistry. 291. 117603–117603.
3.
4.
5.
Miura, Takashi, Tika R. Malla, Lennart Brewitz, et al.. (2024). Cyclic β2,3-amino acids improve the serum stability of macrocyclic peptide inhibitors targeting the SARS-CoV-2 main protease. Bulletin of the Chemical Society of Japan. 97(5). uoae018–uoae018. 12 indexed citations
6.
Chen, Yafen, Yu Nakashima, E. Salah, et al.. (2024). A Small‐Molecule Inhibitor of Factor Inhibiting HIF Binding to a Tyrosine‐Flip Pocket for the Treatment of Obesity. Angewandte Chemie International Edition. 63(40). e202410438–e202410438. 5 indexed citations
7.
Salah, E., C. Johansson, Elisabete Pires, et al.. (2024). JmjC catalysed histone H2a N-methyl arginine demethylation and C4-arginine hydroxylation reveals importance of sequence-reactivity relationships. Communications Biology. 7(1). 1583–1583. 3 indexed citations
8.
Brewitz, Lennart, et al.. (2024). Thiophene-fused γ-lactams inhibit the SARS-CoV-2 main protease via reversible covalent acylation. Chemical Science. 15(20). 7667–7678. 1 indexed citations
9.
Salah, E., et al.. (2024). Crystallographic and Selectivity Studies on the Approved HIF Prolyl Hydroxylase Inhibitors Desidustat and Enarodustat. ChemMedChem. 19(24). e202400504–e202400504. 1 indexed citations
10.
Salah, E., Bhaskar Bhushan, A. Szykowska, et al.. (2024). Focused Screening Identifies Different Sensitivities of Human TET Oxygenases to the Oncometabolite 2-Hydroxyglutarate. Journal of Medicinal Chemistry. 67(6). 4525–4540. 4 indexed citations
11.
Miura, Takashi, Tika R. Malla, David Owen, et al.. (2023). In vitro selection of macrocyclic peptide inhibitors containing cyclic γ2,4-amino acids targeting the SARS-CoV-2 main protease. Nature Chemistry. 15(7). 998–1005. 36 indexed citations
12.
Brewitz, Lennart, Yu Nakashima, E. Salah, et al.. (2023). 5-Substituted Pyridine-2,4-dicarboxylate Derivatives Have Potential for Selective Inhibition of Human Jumonji-C Domain-Containing Protein 5. Journal of Medicinal Chemistry. 66(15). 10849–10865. 7 indexed citations
13.
Wu, Yue, E. Salah, Yu Nakashima, et al.. (2023). Structure-guided optimisation of N-hydroxythiazole-derived inhibitors of factor inhibiting hypoxia-inducible factor-α. Chemical Science. 14(43). 12098–12120. 8 indexed citations
14.
Brewitz, Lennart, David Owen, Stephen M. Laidlaw, et al.. (2023). Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine. Journal of Medicinal Chemistry. 66(4). 2663–2680. 38 indexed citations
15.
Cockman, Matthew E., Yoichiro Sugimoto, Norma Masson, et al.. (2022). Widespread hydroxylation of unstructured lysine-rich protein domains by JMJD6. Proceedings of the National Academy of Sciences. 119(32). e2201483119–e2201483119. 23 indexed citations
16.
Malla, Tika R., Anthony Tumber, Tobias John, et al.. (2021). Mass spectrometry reveals potential of β-lactams as SARS-CoV-2 Mpro inhibitors. Chemical Communications. 57(12). 1430–1433. 32 indexed citations
17.
Nakashima, Yu, Lennart Brewitz, Anthony Tumber, E. Salah, & Christopher J. Schofield. (2021). 2-Oxoglutarate derivatives can selectively enhance or inhibit the activity of human oxygenases. Nature Communications. 12(1). 6478–6478. 23 indexed citations
18.
Malla, Tika R., Anthony Tumber, Lennart Brewitz, et al.. (2021). Structure‐Activity Studies Reveal Scope for Optimisation of Ebselen‐Type Inhibition of SARS‐CoV‐2 Main Protease. ChemMedChem. 17(4). e202100582–e202100582. 23 indexed citations
19.
Brewitz, Lennart, Anthony Tumber, Armin Thalhammer, et al.. (2020). Synthesis of Novel Pyridine‐Carboxylates as Small‐Molecule Inhibitors of Human Aspartate/Asparagine‐β‐Hydroxylase. ChemMedChem. 15(13). 1139–1149. 18 indexed citations
20.
Coutandin, Daniel, Christian Osterburg, Ratnesh Kumar Srivastav, et al.. (2016). Quality control in oocytes by p63 is based on a spring-loaded activation mechanism on the molecular and cellular level. eLife. 5. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Richard A. Norman Breakdown of academic impact, for papers by Tong Ying Shun Breakdown of academic impact, for papers by Jeffrey Tom Breakdown of academic impact, for papers by Maria Fälth Savitski Breakdown of academic impact, for papers by Bainan Wu Breakdown of academic impact, for papers by Guixian Jin Breakdown of academic impact, for papers by Klaus Godl Breakdown of academic impact, for papers by Zoltán Greff Breakdown of academic impact, for papers by Chunli Yan Breakdown of academic impact, for papers by Dominico Vigil
Rankless by CCL
2026